Skip to content

Inspection prep notes · Sterility and contamination control

Disinfection and sporicidal agents

Also called: disinfection, disinfectant, sporicidal agent

FDA looks less at whether disinfectants are on hand than at whether they were used on cleanroom and aseptic area surfaces under the conditions shown to be effective. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Sporicidal agents were not properly used in disinfecting the aseptic area

Your firm failed to use a sporicidal agent as part of your disinfection program for the aseptic processing area and used non-sterile wipes to clean within the area where drug products were filled into syringes.

FDA Warning Letter · Thrive Health and Wellness, LLC dba Thrive Health Solutions · 2026-04-21 · View document

Your firm failed to ensure an adequate contact time for your sporicidal agent used to disinfect your aseptic processing areas.

FDA Warning Letter · Stokes Healthcare Inc. dba Epicur Pharma · 2024-10-22 · View document

2Procedures did not reflect validated contact times

While (b)(4) can be an effective disinfectant, your procedure lacks critical elements such as validated contact times, concentration verification, residue removal, and demonstration that the cleaning process consistently achieves the sterility assurance levels required for sterile drug products.

FDA Warning Letter · Bio-Medical Pharmaceutical Manufacturing Corporation · 2026-02-10

Procedures for sanitization do not always reflect contact times that were determined in your "Report of Qualification of the Efficacy of Disinfectants on Surfaces of the Manufacturing Facility According to Requirements of USP <1072>."

FDA 483 · Kaysersberg Pharmaceuticals SAS · 2026-10-23 · View document

3No efficacy studies were performed for the disinfectants in use

Disinfectant effectiveness studies have not been performed for the sanitizing agents routinely utilized in the manufacturing facility.

FDA 483 · Duke University · 2026-10-30 · View document

However, no disinfectant efficacy studies have been performed to validate the effectiveness of these agents against the relevant microorganisms in your manufacturing environment.

FDA 483 · Apotek Production & Laboratorier AB · 2026-10-22 · View document

4Disinfection efficacy studies did not cover the actual materials and contaminants

Further, the disinfection efficacy studies for (b)(4) did not adequately address all materials of the filling line, including but not limited to, (b)(4) (filling equipment), (b)(4) and (b)(4) , and (b)(4) hose).

FDA Warning Letter · Daewoo Pharmaceutical Co., Ltd. · 2025-07-15 · View document

The disinfection efficacy study does not demonstrate effectiveness against viral contaminants.

FDA 483 · Andelyn Biosciences, Inc. · 2026-10-30 · View document

5Disinfectant was not kept on surfaces for the contact time

It was also observed that non-sterile cleaning and disinfecting agents were used in your cleanroom with inadequate contact times.

FDA Warning Letter · Uriel Pharmacy, Inc. · 2025-11-18 · View document

Disinfection of the area was deficient in that the disinfect was doused on the walls without the proper use of wipes or mops to ensure the disinfectant touches all required surfaces for the expected contact time.

FDA 483 · Gland Pharma Limited · 2026-10-20 · View document

Questions to check against your procedures

  1. Does the disinfection program for the aseptic area include a sporicidal agent?
  2. Is the contact time for the sporicidal agent set in the procedure and achieved in practice?
  3. Do the contact times in the disinfection procedures match those in the disinfectant efficacy report?
  4. Have efficacy studies been performed for every disinfectant in routine use?
  5. Do the efficacy studies cover the materials of the filling line and viral contaminants?
  6. Are wipes and mops used so that the disinfectant reaches every required surface for the contact time?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.